On Monday, Shares of KKR & Co. L.P. (NYSE:KKR), gained 1.86% to $15.85.
KKR & Co. L.P., declared that it has re-launched its pioneering environmental initiative under a new name, and with an expanded mission. KKR’s eight-year-old Green Portfolio Program (GPP), which focused on promoting eco-efficiency best practices across participating portfolio companies, will be expanded to an initiative called the Green Solutions Platform (GSP).
The launch of the GSP follows nearly eight years of meaningful environmental and financial impact from the GPP. During that time period, 27 companies take partd with 25 of those companies reporting the following cumulative results thanks to companies’ eco-efficiency efforts: nearly $1.2 billion in avoided costs and added revenue, more than 2.3 million metric tons of avoided greenhouse gas (GHG) emissions, 27 million cubic meters of avoided water use, and 6.3 million tons of avoided waste.
Evolving beyond this focus on eco-efficiency, the GSP will mobilize a broader spectrum of possible environmental and business impacts. The re-launched program will continue to drive efforts in eco-efficiency, but will also promote and champion participating companies’ environmental innovations and solutions offerings to environmental challenges as part of their business mandate.
KKR & Co. L.P. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, administration buyouts, credit special situations, growth equity, mature, mezzanine, distressed, and middle market investments.
Shares of Amgen, Inc. (NASDAQ:AMGN), inclined 0.30% to $159.28, during its last trading session.
Amgen, declared that the European Commission has approved the use of IMLYGIC™ (talimogene laherparepvec) for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a), with no bone, brain, lung or other visceral disease. IMLYGIC is the first oncolytic immunotherapy to demonstrate therapeutic benefit for patients with metastatic melanoma in a Phase 3 clinical trial.
IMLYGIC is derived from the herpes simplex type 1 virus (HSV-1) , commonly called the cold sore virus. IMLYGIC has been modified to replicate within tumors and to produce the immune stimulatory protein human granulocyte-macrophage colony-stimulating factor (GM-CSF). Administered via intralesional injection, IMLYGIC is designed to cause the death of tumor cells and initiate an anti-tumor immune response.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
Finally, Eli Lilly and Co (NYSE:LLY), ended its last trade with 1.50% gain, and closed at $86.04.
Halozyme Therapeutics, declared a global partnership and license agreement with Eli Lilly and Company (LLY) to develop and commercialize products combining proprietary Lilly compounds with Halozyme’s ENHANZE™ platform.
Under the terms of the agreement, Halozyme will receive an initial $25 million payment, followed by milestone payments of up to $160 million for each of up to five partnership targets valued at up to $800 million. These payments are subject to Lilly’s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay Halozyme mid-single digit royalties if products under the partnership are commercialized.
The Halozyme ENHANZE platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan — a chain of natural sugars in the body — to aid in the dispersion and absorption of other injected therapeutic drugs. For Lilly, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
